Researcher leads first in-human multiple myeloma study with over 90% response rate

by

Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with relapsed multiple myeloma. Patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5% overall response rate.

Leave A Comment

Your email address will not be published. Required fields are marked *